Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jan Cerny"'
Autor:
Lloyd Hutchinson, Muthalagu Ramanathan, Patricia M. Miron, Anne W. Higgins, Asiri Ediriwickrema, Jonathan M. Gerber, Jan Cerny, Maxwell R Lloyd, Qiming Shi, Karl Simin, Shyam A. Patel
Publikováno v:
Leukemia & Lymphoma. 62:3348-3360
TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia have dismal outcomes. Here, we define the clinico-genomic landscape of TP53 disruptions in 40 patients and employ clonal dynamic modeling to map the mutational hierarchy against clinic
Publikováno v:
Leukemia & Lymphoma. 62:2022-2025
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25% of non-Hodgkin lymphoma cases [1]. Although often treatment-responsive, 30–40% of DLBCL patients develop refractory or relapsed ...
Autor:
Ayman Saad, Gregory A. Hale, Richard F. Olsson, Guillermo Garcia-Manero, Jane L. Liesveld, Farhad Ravandi, Kwang Woo Ahn, Sachiko Seo, Jan Cerny, Aaron T. Gerds, Michael R. Grunwald, Rammuriti T. Kamble, Taiga Nishihori, Melhem Solh, Xiao Lin, Srdan Verstovsek, Richard E. Champlin, Bipin N. Savani, Ronald Sobecks, Gorgun Akpek, Edwin P. Alyea, Mark R. Litzow, Celalettin Ustun, Hans C. Lee, Xuelin Huang, Andrew Daly, Mahmoud Aljurf, Ulrike Bacher, Hagop M. Kantarjian, Zachariah DeFilipp, Wael Saber, Jorge E. Cortes, Bei Hu, Tamila L. Kindwall-Keller, Bart L. Scott, Marcos de Lima, Nasheed Hossain, Uday R. Popat, Zhen-Huan Hu, Yoshihiro Inamoto, Mohamed A. Kharfan-Dabaja, David I. Marks, Jack W. Hsu, Rebecca S. S. Tidwell, Baldeep Wirk, Elias Jabbour
Publikováno v:
Leukemia & Lymphoma. 61:2811-2820
While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or
Autor:
Witold B. Rybka, Mark R. Litzow, Hillard M. Lazarus, Jan Cerny, Xin Victoria Wang, Jacob M. Rowe, Martin S. Tallman, Stephen A. Strickland
Publikováno v:
Leukemia & Lymphoma. 61:2191-2199
High-dose cytarabine (HiDAC) consolidation for acute myeloid leukemia (AML) induces transient profound myelosuppression and potential morbidity/mortality. PrE0901 was a phase I multi-center trial evaluating the safety/toxicity of eltrombopag in AML p